Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 5, 2011, Pages 364-368

  Liu, Hsin Yi ^a   Lin, Hsiu Chen ^a   Lin, Yi Chun ^a   Yu, Shao hua ^a   Wu, Wui Hsiu ^a   Lee, Yuarn Jang ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAMASE; CIPROFLOXACIN; COTRIMOXAZOLE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; NITROFURANTOIN;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BROTH DILUTION; COMPARATIVE STUDY; DISK DIFFUSION; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TAIWAN; TEACHING HOSPITAL;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FOSFOMYCIN; HOSPITALS, TEACHING; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; NITROFURANTOIN; TAIWAN; URINARY TRACT INFECTIONS;

EID: 80053632860     PISSN: 16841182     EISSN: 19959133     Source Type: Journal    
DOI: 10.1016/j.jmii.2010.08.012     Document Type: Article

References (26)

1. Gupta K. Emerging antibiotic resistance in urinary tract pathogens. Infect Dis Clin North Am 2003, 17:243-259.
2. Falagas M.E., Polemis M., Alexiou V.G., Marini-Mastrogiannaki A., Kremastinou J., Vatopoulos A.C. Antimicrobial resistance of Esherichia coli urinary isolates from primary care patients in Greece. Med Sci Monit 2008, 14:CR75-CR79.
3. Paterson D.L., Bonomo R.A. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
4. Eschenburg S., Priestman M., Schonbrunn E. Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine enolpyruvyl transferase (MurA) is essential for product release. J Biol Chem 2005, 280:3757-3763.
5. Kahan F., Kahan J., Cassidy P., Kropp H. The mechanism of action of fosfomycin (phosphonomycin). Ann N Y Acad Sci 1974, 235:364-386.
6. Clinical and Laboratory Standards Institue Performance standards for antimicrobial susceptibility testing 2009, Supplement M100-S19, Clinical and Laboratory Standards Institue, Wayne, PA.
7. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:28-40.
8. Horan T.C., Andrus M., Dudeck M.A. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting; 2008. Am J Infect Control 2008, 36:309-332.
9. Jean S.S., Teng L.J., Hsueh P.R., Ho S.W., Luh K.T. Antimicrobial susceptibilities among cilinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. J Antimicrob Chemother 2002, 49:69-76.
10. Paterson D.L., Mulazimoglu L., Casellas J.M., Ko W.C., Goossens H., Von Gottberg A.V., et al. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum β-lactamase production in Klebsiella pneumoniae isolates causing bacteremia. Clin Infect Dis 2000, 30:473-478.
11. Lautenbach E., Strom B.L., Bilker W.B., Patel J.B., Edelstein P.H., Fishman N.O. Epidemiology investigation of fluoroquinolone resistance in infections due to extended-spectrumβ-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin Infect Dis 2001, 33:1288-1294.
12. Liao C.H., Sheng W.H., Wang J.T., Sun H.Y., Wang H.K., Hsueh P.R., et al. In vitro activities of 16 antimicrobial agents against clinical isolates of extended-spectrumβ-lactamase-producing Escherichia coli and Klebsiella pneumoniae in two regional hospitals in Taiwan. J Microbiol Immunol Infect 2006, 39:59-66.
13. Hawser S.P., Bouchillon S.K., Hoban D.J., Badal R.E. In vitro susceptibilities of aerobic and facultative anaerobic Gram-negative bacilli from patients with intra-abdominal infections worldwide from 2005-2007: results from the SMART study. Int J Antimicrob Agents 2009, 34:585-588.
14. Ko K.S., Suh J.Y., Peck K.R., Lee M.Y., Oh W.S., Kwon K.T., et al. In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum β-lactamase-producing Escherichia coli isolated from urine and blood. Diagn Microbiol Infect Dis 2007, 58:111-115.
15. de Cueto M., Lopez L., Hernandez J.R., Morillo C., Pascual A. In vitro activity of fosfomycin against extended-spectrum-β-lactamase producing Escherichia coli and Klebsiella pneumoniae: comparison of susceptibility testing procedures. Antimicrob Agents Chemother 2006, 50:368-370.
16. Canton R., Coque T.M. The CTX-M β-lactamase pandemic. Curr Opin Microbiol 2006, 9:466-475.
17. Yu W.L., Jones R.N., Hollis R.J., Messer S.A., Biedenbach D.J., Deshpande L.M., et al. Molecular epidemiology of extended-spectrum-β-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002, 40:4666-4669.
18. Yan J.J., Ko W.C., Tsai S.H., Wu H.M., Jin Y.T., Wu J.J. Dissemination of CTX-M-3 and CMY-2 β-lactamases among clinical isolates of Escherichia coli in southern Taiwan. J Clin Microbiol 2000, 38:4320-4325.
19. Heffernan H.M., Woodhouse R.E., Pope C.E., Blackmore T.K. Prevalence and types of extended-spectrum-β-lactamase among urinary Escherichia coli and Klebsiella spp. in New Zealand. Int J Antimicrob Agents 2009, 34:544-549.
20. Prakash V., Lewis J.S., Herrera M.L., Wickes B.L., Jorgensen J.H. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum β-lactamases. Antimicrob Agents Chemother 2009, 53:1278-1280.
21. Ho P.L., Wong R.C., Yip K.S., Loke S.L., Leung M.S., Mak G.C., et al. Antimicrobial resistance in Escherichia coli outpatient urinary isolates from women: emerging multidrug resistance phenotypes. Diagn Microbiol Infect Dis 2007, 59:439-445.
22. Falagas M.E., Kastoris A.C., Kapaskelis A.M., Karageogropoulos D.E. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010, 10:43-50.
23. Falagas M.E., Kanellopoulou M.D., Karageorgopoulos D.E., Dimopoulos G., Rafailidis P.I., Skarmoutsou N.D., et al. Antimicrobial susceptibility of multidrug-resistant Gram negative bacteria to fosfomycin. Eur J Clin Microbiol Infect Dis 2008, 27:439-443.
24. Kashanian J., Hakimian P., Blute M., Wong J., Khanna H., Wise G., et al. Nitrofurantoin: the return of an old friend in the wake of growing resistance. BJU Int 2008, 102:1634-1637.
25. Procop G.W., Tuohy M.J., Wilson D.A., Williams D., Hadziyannis E., Hall G.S. Cross-class resistance to non-β-lactam antimicrobials in extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Am J Clin Pathol 2003, 120:265-267.
26. Melzer M., Peterson I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007, 55:254-259.